Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China

Oct 15, 2019 21:24 JST

Source: Eisai

TOKYO, Oct 15, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older. Fycompa was designated for Priority Review by the NMPA due to its significant clinical benefits compared to existing treatments, and was approved in about 12 months since the submission in September 2018.

In China, it is estimated that there are approximately 9 million patients with epilepsy, approximately 60% of whom being affected by partial-onset seizures. About 40% patients with partial-onset seizures require adjunctive treatment.1 As approximately 30% of patients with epilepsy are unable to control their seizures with currently available AEDs,2 this is a disease with significant unmet medical needs.

Fycompa is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. Administered orally once-daily, it is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes.

Fycompa has been approved in over 60 countries around the world as an adjunctive treatment for partial- onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older. In addition, Fycompa has been approved in over 55 countries as an adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. In the United States, Fycompa is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older.

Eisai considers neurology including epilepsy, a therapeutic area of focus. With this approval of Fycompa in China, Eisai pursues our mission to provide "seizure freedom" to a greater number of patients with epilepsy across the world living. Eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

Contact:

Eisai Co., Ltd. 
Public Relations Department
+81-(0)3-3817-5120

Source: Eisai
Sectors: Healthcare & Pharm

Related Press Release

Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

April 21 2026 19:52 JST

Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy

March 27 2026 19:14 JST

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

March 27 2026 17:19 JST

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026

March 23 2026 10:19 JST

Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)

March 19 2026 09:54 JST

Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation

March 17 2026 18:49 JST

Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration

March 12 2026 16:21 JST

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting

March 11 2026 11:07 JST

WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

March 02 2026 08:49 JST

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy

February 16 2026 13:03 JST

More Press release >>

Latest Press Release

ULVAC Establishes Japan-Based Production for Rare-Earth Magnet Vacuum Melting Furnaces
May 01, 2026 11:00 JST

teamLab Borderless Ranked Among the World's 100 Most Visited Art Museums and 4th in Japan
Apr 30, 2026 21:00 JST

TANAKA to Showcase Advanced Semiconductor Materials and Circular Economy Initiatives at SEMICON Southeast Asia 2026
Apr 28, 2026 21:00 JST

NEC Launches "Africa Corporate Innovation Program" Accelerating Business Through Co-Creation with African Startups
Apr 28, 2026 19:05 JST

Advancing Early Detection: OMRON Healthcare Supports May Measurement Month 2026
Apr 28, 2026 01:00 JST

NEC Announces Strategic Collaboration with Anthropic Focused on Enterprise AI
Apr 23, 2026 17:46 JST

Fujitsu and Carnegie Mellon University launch joint center for Physical AI
Apr 23, 2026 17:19 JST

China Gas Signs Strategic Cooperation Agreement with CITIC Construction and China CITIC Bank

Apr 22, 2026 21:32 JST

CBL International Limited Acquires Majority Stake in Green Marine Energy Holdings Limited
Apr 22, 2026 21:15 JST

OMRON Healthcare and Tricog Health strengthen collaboration in India with Tricog CardioCheck (TCC)
Apr 22, 2026 19:30 JST

MHI Marine Machinery & Equipment and Mitsubishi Shipbuilding Obtain Approval in Principle (AiP) for the Basic Design of a Methane Oxidation Catalyst System for Marine LNG-Fueled Engines from Classification Society ClassNK
Apr 22, 2026 17:16 JST

NEC Receives Company of the Year recognition in Global Biometric Solutions from Frost & Sullivan
Apr 22, 2026 14:46 JST

MHIEC Completes Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kagoshima City

Apr 22, 2026 11:13 JST

MHIEC Completes Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Sendai City
Apr 22, 2026 11:03 JST

Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Apr 21, 2026 20:52 JST

Hitachi to establish a new company with Nojima under a strategic partnership to accelerate growth of its home appliance business
Apr 21, 2026 19:21 JST

BULL and Fujitsu Sign Basic Agreement to Develop Japan's Unique High-Precision Space Situational Awareness Service
Apr 21, 2026 11:47 JST

Fujitsu launches GLOVIA One ERP solution for mid-sized Japanese enterprises
Apr 20, 2026 11:46 JST

NEC to Supply Nine Types of Defense Equipment for Tthree Australian Frigates
Apr 19, 2026 12:10 JST

Mitani Sangyo Filed U.S. Patent Application for AI Reliability Governance Framework
Apr 17, 2026 00:00 JST

More Latest Release >>